Jim Biagi

1.2k total citations
17 papers, 648 citations indexed

About

Jim Biagi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Jim Biagi has authored 17 papers receiving a total of 648 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Jim Biagi's work include Ovarian cancer diagnosis and treatment (5 papers), Endometrial and Cervical Cancer Treatments (4 papers) and Clinical practice guidelines implementation (3 papers). Jim Biagi is often cited by papers focused on Ovarian cancer diagnosis and treatment (5 papers), Endometrial and Cervical Cancer Treatments (4 papers) and Clinical practice guidelines implementation (3 papers). Jim Biagi collaborates with scholars based in Canada, United States and United Kingdom. Jim Biagi's co-authors include Laurie Elit, Amit M. Oza, Paul Hoskins, Janet Dancey, Elizabeth A. Eisenhauer, Diane Provencher, Prafull Ghatage, Ming‐Sound Tsao, Helen Mackay and Walter H. Gotlieb and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and Gynecologic Oncology.

In The Last Decade

Jim Biagi

15 papers receiving 643 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jim Biagi Canada 10 275 252 238 158 106 17 648
J. Mazurka Canada 10 177 0.6× 170 0.7× 167 0.7× 120 0.8× 68 0.6× 15 488
Isabelle Laure Ray-Coquard France 15 423 1.5× 101 0.4× 155 0.7× 625 4.0× 103 1.0× 110 852
Tomoko Wakasa Japan 16 83 0.3× 61 0.2× 141 0.6× 207 1.3× 111 1.0× 85 767
John W. McBroom United States 13 96 0.3× 127 0.5× 106 0.4× 133 0.8× 39 0.4× 18 546
Hans-Joachim Lueck Germany 14 287 1.0× 144 0.6× 81 0.3× 532 3.4× 86 0.8× 37 917
Mario Nardi Italy 12 442 1.6× 203 0.8× 53 0.2× 350 2.2× 71 0.7× 27 890
Eric Pujade‐Lauraine France 5 1.1k 3.9× 484 1.9× 125 0.5× 283 1.8× 67 0.6× 9 1.2k
Toshiko Minamoto Japan 13 130 0.5× 162 0.6× 122 0.5× 262 1.7× 205 1.9× 34 538
Farnaz Dadmanesh United States 13 133 0.5× 96 0.4× 100 0.4× 197 1.2× 219 2.1× 33 634
Gary C. Reid United States 16 683 2.5× 980 3.9× 185 0.8× 263 1.7× 110 1.0× 23 1.3k

Countries citing papers authored by Jim Biagi

Since Specialization
Citations

This map shows the geographic impact of Jim Biagi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jim Biagi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jim Biagi more than expected).

Fields of papers citing papers by Jim Biagi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jim Biagi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jim Biagi. The network helps show where Jim Biagi may publish in the future.

Co-authorship network of co-authors of Jim Biagi

This figure shows the co-authorship network connecting the top 25 collaborators of Jim Biagi. A scholar is included among the top collaborators of Jim Biagi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jim Biagi. Jim Biagi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Kelly, Deirdre, Derek J. Jonker, Yoo‐Joung Ko, et al.. (2022). GATA6 Expression as a predictor of response to perioperative chemotherapy in resectable pancreatic adenocarcinoma: A multicenter Canadian phase II study (NeoPancONE).. Journal of Clinical Oncology. 40(4_suppl). TPS638–TPS638. 9 indexed citations
2.
3.
Auer, Rebecca C., et al.. (2020). Indications for Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery: A Clinical Practice Guideline. Current Oncology. 27(3). 146–154. 24 indexed citations
4.
Auer, Rebecca C., et al.. (2020). Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review. European Journal of Cancer. 127. 76–95. 57 indexed citations
5.
Enríquez, Andrés, Jim Biagi, Damian Redfearn, et al.. (2016). Increased Incidence of Ventricular Arrhythmias in Patients With Advanced Cancer and Implantable Cardioverter-Defibrillators. JACC. Clinical electrophysiology. 3(1). 50–56. 30 indexed citations
6.
7.
Fung‐Kee‐Fung, Michael, Erin B. Kennedy, Jim Biagi, et al.. (2015). An Organizational Guideline for Gynecologic Oncology Services. International Journal of Gynecological Cancer. 25(4). 551–558. 15 indexed citations
8.
Fung‐Kee‐Fung, Michael, Erin B. Kennedy, Jim Biagi, et al.. (2015). The Optimal Organization of Gynecologic Oncology Services: A Systematic Review. Current Oncology. 22(4). 282–293. 44 indexed citations
9.
Fung‐Kee‐Fung, Michael, Jim Biagi, Terrence J. Colgan, et al.. (2015). Organizational Guideline for Gynecologic Oncology Services in Ontario. 2 indexed citations
10.
Oza, Amit M., Laurie Elit, Ming‐Sound Tsao, et al.. (2011). Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group. Journal of Clinical Oncology. 29(24). 3278–3285. 253 indexed citations
11.
Oza, Amit M., Elizabeth A. Eisenhauer, Laurie Elit, et al.. (2008). Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148. Journal of Clinical Oncology. 26(26). 4319–4325. 97 indexed citations
12.
Molckovsky, Andrea, Suresh Vijay, Wilma M. Hopman, et al.. (2008). Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients. International Journal of Gynecological Cancer. 18(1). 8–13. 1 indexed citations
13.
Fyles, Anthony, L. Elit, Paul Hoskins, et al.. (2004). Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCIC CTG IND-148. Journal of Clinical Oncology. 22(14_suppl). 5019–5019. 3 indexed citations
14.
Fyles, Anthony, L. Elit, Paul Hoskins, et al.. (2004). Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCIC CTG IND-148. Journal of Clinical Oncology. 22(14_suppl). 5019–5019. 17 indexed citations
15.
Biagi, Jim & E. A. Eisenhauer. (2003). Systemic treatment policies in ovarian cancer: the next 10 years. International Journal of Gynecological Cancer. 13. 231–240. 9 indexed citations
16.
Biagi, Jim, et al.. (2000). Primary Hodgkin's disease of the CNS in an immunocompetent patient: Acase study and review of the literature. Neuro-Oncology. 2(4). 239–243. 25 indexed citations
17.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. Mazurka Breakdown of academic impact, for papers by Isabelle Laure Ray-Coquard Breakdown of academic impact, for papers by Tomoko Wakasa Breakdown of academic impact, for papers by John W. McBroom Breakdown of academic impact, for papers by Hans-Joachim Lueck Breakdown of academic impact, for papers by Mario Nardi Breakdown of academic impact, for papers by Eric Pujade‐Lauraine Breakdown of academic impact, for papers by Toshiko Minamoto Breakdown of academic impact, for papers by Farnaz Dadmanesh Breakdown of academic impact, for papers by Gary C. Reid
Rankless by CCL
2026